Cargando…

MON-464 Non-Clinical Profiling of ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) Agonist, to Support Studies in Humans

Somatostatin analogues (SSAs) are indicated for use in acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP NETs). However, SSAs are administered as injections which can be a challenge for patients and healthcare providers. ONO-5788 is a novel low molecular weight orally administered mol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Komagata, Tatsuya, Tanaka, Hirotaka, Ishida, Akiharu, Sawada, Takeshi, Neki, Shinichi, Iida, Hiroyuki, Okada, Hiroki, Katsumata, Seishi, Shinozaki, Koji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550742/ http://dx.doi.org/10.1210/js.2019-MON-464

Ejemplares similares

MON-477 Octreotide and ONO-ST-468, a Novel and Potent Somatostatin Receptor Type-2 (SST2) Agonist, Suppress GH Hypersecretion in the Monkey
por: Tanaka, Hirotaka, et al.
Publicado: (2019)

MON-459 ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) Agonist, Attenuates GH Hypersecretion in Human GH-Secreting, Pituitary Adenoma-Derived Cells
por: Zhou, Cuiqi, et al.
Publicado: (2019)

SAT-430 A Phase 1 Study in Healthy Volunteers to Assess the Safety, Tolerability, and Pharmacokinetics of ONO-5788: A Novel Oral Small Molecule Somatostatin Receptor Type-2 Agonist
por: Kaviya, Arpeat, et al.
Publicado: (2019)

MON-467 Expression of Somatostatin Receptors in Aggressive Non-Functioning Pituitary Adenomas
por: Soto, Alfonso, et al.
Publicado: (2019)

MON-288 TSH Deficiency in Patients on Somatostatin Analog for TSH-PitNET
por: Illouz, Frederic, et al.
Publicado: (2020)

MON-465 SST2 Trafficking Through The Cytoskeleton: Role Of Scaffolding Proteins Filamin A And β-arrestin 2
por: Treppiedi, Donatella, et al.
Publicado: (2019)

SAT-LB076 T2-Signal Intensity, SST Receptor Expression and First-Generation Somatostatin Analogues Efficacy Predict Hormone and Tumor Responses to Pasireotide in Acromegaly
por: Coopmans, Eva, et al.
Publicado: (2019)

SAT-464 Management of an Aggressive Growth Hormone Producing Pituitary Macroadenoma
por: Ayyoub, Sanaa, et al.
Publicado: (2019)

MON-LB50 Poor Response to Pre-Surgical Treatment With Somatostatin Receptor Ligands Is Associated With Diabetes Mellitus in Patients With Acromegaly
por: Frara, Stefano, et al.
Publicado: (2020)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

OR23-05 Human Absorption, Metabolism, Excretion, and Absolute Oral Bioavailability of (14)C-CRN00808, an Orally Bioavailable, Nonpeptide, Selective, Somatostatin Receptor 2 (sST2) Biased Agonist for the Treatment of Acromegaly
por: Madan, Ajay, et al.
Publicado: (2020)

MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

SAT-429 Final Results from the First in Man Phase 1 Clinical Trial of CRN00808, an Orally Bioavailable sst2-Selective, Nonpeptide Somatostatin Biased Agonist, for the Treatment of Acromegaly: Safety, Pharmacokinetics, Pharmacodynamics, and Midazolam Drug Interaction in Healthy Volunteers
por: Madan, Ajay, et al.
Publicado: (2019)

MON-297 Withdrawal from Long-Acting Somatostatin Receptor Ligand Injections in Adult Patients with Acromegaly: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

MON-323 IGF-I Variability and Its Association with Demographic and Clinical Characteristics in Patients with Acromegaly Treated with Injectable Somatostatin Receptor Ligands (SRLS); Results from an International Prospective Phase III Study
por: Samson, Susan Leanne, et al.
Publicado: (2020)

OR23-04 SST5 Expression and USP8 Mutation in Functioning and Silent Corticotroph Pituitary Tumors
por: castellnou, Solene, et al.
Publicado: (2020)

MON-430 To B, or Not to B
por: Pradeep, Pallavi, et al.
Publicado: (2019)

FRI296 Somatostatin Receptor 5 Staining In Prolactinomas
por: Mehta, Sonal, et al.
Publicado: (2023)

MON-LB46 Thyrotropinoma and Pregnancy
por: Namboodiri, Divya, et al.
Publicado: (2020)

MON-LB55 Biochemical Control of Most Patients Reverting to Injectable Long-Acting Somatostatin Receptor Ligands Is Achieved After One Dose: Results From the Phase 3, Randomized, Double Blind, Placebo-Controlled Optimal Study
por: Fleseriu, Maria, et al.
Publicado: (2020)

Olfactory Neuroblastoma: The Adjunctive Role of Somatostatin Agonists After Surgery
por: Toral, Fernando Pazos, et al.
Publicado: (2021)

Somatostatin, as a Bridge Between the GH-Axis and the Gth-Axis
por: Mizrahi, Naama, et al.
Publicado: (2021)

MON-305 Clinical Features in Patients with Hypercorticism
por: Negmatova, Gulzoda Shuhratovna, et al.
Publicado: (2020)

MON-425 SIADH with Epistaxis: Rule out Esthesioneuroblastoma
por: Diamond, Samantha, et al.
Publicado: (2019)

MON-266 The Association Between Prolactinomas and Weight Gain
por: Tariq, Zunera, et al.
Publicado: (2020)

MON-289 Pituitary Metastasis: A Systematic Review
por: Parekh, Shrina, et al.
Publicado: (2020)

MON-LB48 The Genomic Landscape of Sporadic Thyrotrophinomas
por: shen, Angeline, et al.
Publicado: (2020)

MON-302 The Prevalence of Acromegaly in the Sleep Apnoea Clinic
por: Lynch, Julie Marie, et al.
Publicado: (2020)

MON-244 Adenocarcinoma Pituitary Metastasis with Suprasellar Extension
por: Reddy, Nithin Modhugu, et al.
Publicado: (2020)

MON-434 Familial Alactogenesis Associated with a Prolactin Mutation
por: Moriwaki, Mika, et al.
Publicado: (2019)

MON-441 Copeptin Response to Acute Hypoglycemia in Children and Adolescents
por: Drummond, Juliana, et al.
Publicado: (2019)

MON-423 Unique Neuroendocrine Manifestation of Necrotizing Sarcoid Granulomatosis
por: Finn, Victoria, et al.
Publicado: (2019)

MON-409 Ectopic ACTH Syndrome with a Pituitary Mass
por: Lake, Julia, et al.
Publicado: (2019)

MON-414 The Case of a Dual-Secreting Pituitary Macroadenoma
por: Malkani, Natasha, et al.
Publicado: (2019)

MON-443 Periostin Concentrations in Childhood-Onset Craniopharyngioma Patients
por: Heinks, Kerstin, et al.
Publicado: (2019)

MON-285 Clinical Characteristics of Six Patients with Infundibulo-Neurohypophysitis
por: Nao, Keiko, et al.
Publicado: (2020)

MON-260 Sinonasal Papilloma Masquerading as a Pituitary Macroadenoma
por: Cohen, Melissa, et al.
Publicado: (2020)

MON-270 Diagnostic Value of Copeptin in Central Diabetes Insipidus
por: Boehm, Emma, et al.
Publicado: (2020)

MON-296 Craniopharyngiomas Presenting as Incidentalomas: Results of Kraniopharyngeom 2007
por: Boekhoff, Svenja, et al.
Publicado: (2020)

MON-LB52 Evaluation of Arterial Stiffness in Acromegaly Patients
por: alagüney, sevil, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qdm9vhajd40f5qaf64lkih812f